The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2024 | Assessing treatment options for lung cancer with interstitial lung disease
Matthew Hatton, MBChB, MSc, FRCP, FRCR, University of Sheffield, Sheffield, UK, emphasizes the importance of careful patient assessment when considering treatment options for lung cancer with interstitial lung disease (ILD). He underscores the need to evaluate both the cancer itself and the patient’s overall health to determine if potentially curative treatments are viable. However, he acknowledges that treatments such as surgery and radiotherapy pose higher risks for these patients due to their underlying ILD. Therefore, treatment decisions must be made by considering the balance between potential benefits and risks, with active involvement from the patient in the decision-making process. This interview took place at the BTOG 2024 congress in Belfast, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
